

Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-Aug-2014
 Document Type: USP Monographs
 DocId: GUID-2E04FD0E-AF60-4EC5-8C03-D3E3598A84B2_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M53338_01_01
 DOI Ref: 7r8fu

© 2025 USPC
 Do not distribute

Metoclopramide Oral Solution

DEFINITION

Metoclopramide Oral Solution contains an amount of metoclopramide hydrochloride ($C_{14}H_{22}ClN_3O_2 \cdot HCl \cdot H_2O$) equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of metoclopramide ($C_{14}H_{22}ClN_3O_2$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Mobile phase: Dissolve 2.7 g of sodium acetate in 600 mL of water, and add 400 mL of acetonitrile and 4 mL of tetramethylammonium hydroxide solution in methanol (25%). Adjust with glacial acetic acid to a pH of 6.5, filter, and degas.

System suitability stock solution: Transfer 125 mg of benzenesulfonamide to a 25-mL volumetric flask. Add 15 mL of methanol, and shake to dissolve. Dilute with 0.01 M phosphoric acid to volume.

Standard stock solution: 9 mg/mL of [USP Metoclopramide Hydrochloride RS](#) in 0.01 M phosphoric acid

System suitability solution: Transfer 15 mL of *System suitability stock solution* and 5 mL of *Standard stock solution* into a 250-mL volumetric flask, and dilute with 0.01 M phosphoric acid to volume.

Standard solution: 180 µg/mL of [USP Metoclopramide Hydrochloride RS](#) (equivalent to 160 µg/mL of metoclopramide) from *Standard stock solution*. Dilute with 0.01 M phosphoric acid.

Sample solution: Nominally 160 µg/mL of metoclopramide, prepared as follows. Transfer a volume of Oral Solution, equivalent to about 4 mg of metoclopramide, to a 25-mL volumetric flask, and dilute with 0.01 M phosphoric acid to volume.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 215 nm or diode array. [NOTE—Use the diode array detector to perform *Identification* test B.]

Column: 4.6-mm × 25-cm; packing L1

Flow rate: 1.5 mL/min

Injection volume: 20 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

[NOTE—The relative retention times for benzenesulfonamide and metoclopramide are 0.2 and 1.0, respectively.]

Resolution: NLT 1.5 between the benzenesulfonamide and metoclopramide peaks, *System suitability solution*

Tailing factor: NMT 2.0 for the metoclopramide peak, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of metoclopramide ($C_{14}H_{22}ClN_3O_2$) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration from [USP Metoclopramide Hydrochloride RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of metoclopramide in the *Sample solution* (µg/mL)

M_{r1} = molecular weight of metoclopramide, 299.80

M_{r2} = molecular weight of anhydrous metoclopramide hydrochloride, 336.26

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#)

For oral solution packaged in single-unit containers: Meets the requirements

• [DELIVERABLE VOLUME \(698\)](#)

For oral solution packaged in multiple-unit containers: Meets the requirements

IMPURITIES

• ORGANIC IMPURITIES

Mobile phase: Prepare a 1.88 g/L solution of sodium 1-hexanesulfonate solution (0.01 M solution) in a mixture of acetonitrile and water (60:40), and adjust with glacial acetic acid to a pH of 4.0.

Standard solution: 5.5 µg/mL of [USP Metoclopramide Hydrochloride RS](#) in *Mobile phase*

Sample solution: Dilute a volume of Oral Solution with *Mobile phase* to obtain a solution containing about 1.0 mg/mL of metoclopramide.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 265 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 2 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.8

Relative standard deviation: NMT 5.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of any individual impurity in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of metoclopramide from the *Standard solution*

C_S = concentration of [USP Metoclopramide Hydrochloride RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of metoclopramide in the *Sample solution* (µg/mL)

M_{r1} = molecular weight of metoclopramide, 299.80

M_{r2} = molecular weight of anhydrous metoclopramide hydrochloride, 336.26

Acceptance criteria: NMT 0.5% of any individual impurity is found. Disregard any peak with a relative retention time of 0.5 or less.

SPECIFIC TESTS

• [pH \(791\)](#): 2.0–5.5

ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, and store at controlled room temperature. Protect from freezing.

• [USP REFERENCE STANDARDS \(11\)](#)

[USP Metoclopramide Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METOCLOPRAMIDE ORAL SOLUTION	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(3)

Current DocID: GUID-2E04FD0E-AF60-4EC5-8C03-D3E3598A84B2_1_en-US

DOI: https://doi.org/10.31003/USPNF_M53338_01_01

DOI ref: [7r8fu](#)

OFFICIAL